These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23107788)

  • 41. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
    Ayatollahi H; Shajiei A; Sadeghian MH; Sheikhi M; Yazdandoust E; Ghazanfarpour M; Shams SF; Shakeri S
    Hematol Oncol Stem Cell Ther; 2017 Mar; 10(1):1-7. PubMed ID: 27613372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
    Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
    Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
    Bullinger L; Rücker FG; Kurz S; Du J; Scholl C; Sander S; Corbacioglu A; Lottaz C; Krauter J; Fröhling S; Ganser A; Schlenk RF; Döhner K; Pollack JR; Döhner H
    Blood; 2007 Aug; 110(4):1291-300. PubMed ID: 17485551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
    Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
    Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
    Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of a Prognostic Model for Overall Survival Adult Patients with Core Binding Factor Acute Myeloid Leukaemia].
    Shi LY; Li LL; Li T; Li YF; Liu YF; Jiang ZX; Wang SJ; Wang C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):693-701. PubMed ID: 38926955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
    Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
    Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
    Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
    Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
    [No Abstract]   [Full Text] [Related]  

  • 50. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
    Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia.
    Yang J; Yao DM; Ma JC; Yang L; Guo H; Wen XM; Xiao GF; Qian Z; Lin J; Qian J
    Tumour Biol; 2016 Aug; 37(8):10107-14. PubMed ID: 26820131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
    Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population.
    Wei H; Wang Y; Zhou C; Lin D; Liu B; Liu K; Qiu S; Gong B; Li Y; Zhang G; Wei S; Gong X; Liu Y; Zhao X; Gu R; Mi Y; Wang J
    J Hematol Oncol; 2018 Feb; 11(1):18. PubMed ID: 29427994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Paschka P; Schlenk RF; Weber D; Benner A; Bullinger L; Heuser M; Gaidzik VI; Thol F; Agrawal M; Teleanu V; Lübbert M; Fiedler W; Radsak M; Krauter J; Horst HA; Greil R; Mayer K; Kündgen A; Martens U; Heil G; Salih HR; Hertenstein B; Schwänen C; Wulf G; Lange E; Pfreundschuh M; Ringhoffer M; Girschikofsky M; Heinicke T; Kraemer D; Göhring G; Ganser A; Döhner K; Döhner H
    Leukemia; 2018 Jul; 32(7):1621-1630. PubMed ID: 29720733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
    Lück SC; Russ AC; Du J; Gaidzik V; Schlenk RF; Pollack JR; Döhner K; Döhner H; Bullinger L
    Br J Haematol; 2010 Mar; 148(6):925-37. PubMed ID: 20064158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Genetic abnormalities in core binding factor acute myeloid leukemia].
    Ishikawa Y
    Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
    Santos FP; Jones D; Qiao W; Cortes JE; Ravandi F; Estey EE; Verma D; Kantarjian H; Borthakur G
    Cancer; 2011 May; 117(10):2145-55. PubMed ID: 21523727
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia.
    Jang W; Yoon JH; Park J; Lee GD; Kim J; Kwon A; Choi H; Han K; Nahm CH; Kim HJ; Min WS; Kim M; Kim Y
    Blood Cancer J; 2016 Jan; 6(1):e387. PubMed ID: 26771813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.